Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 1.00 |
| ▸ | MMP3 | P08254 | 5/20 | 1.00 |
| ▸ | MMP9 | P14780 | 2/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 4/20 | 0.76 |
| ▸ | MMP7 | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 | P45452 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368148 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10429973 | 0.90 | MMP1 (0.82) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10429916 | 0.87 | MMP1 (0.77) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10451735 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL15505966 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10451722 | 0.84 | MMP1 (0.83) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL9650310 | 0.83 | MMP1 (0.86) | MMP1MMP3MMP9ADAM17 | |
| SCHEMBL7276467 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17 | |
| SCHEMBL7284842 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL7278285 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| WO-2011011181-A1 | PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP1 2/4885MMP3 11/4885MMP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.